Investment
Features
FeesSafety
Academy
More
Pluang+

Compare The Coca-Cola Co K (KO) vs Organon & Co. Common Stock (OGN) Price & Performance

The Coca-Cola Co KTrade
Organon & Co. Common StockTrade

Price performance (Past 24H)

Key statistics

The Coca-Cola Co K vs Organon & Co. Common Stock — how do they compare? The Coca-Cola Co K trades at $92.95 (market cap $387.70B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: The Coca-Cola Co K is far larger — about 107.1× Organon & Co. Common Stock's market cap, and The Coca-Cola Co K pays the higher dividend (2.35%). Which is the better fit depends on your goals — on Pluang, investors hold The Coca-Cola Co K for 154 Days and Organon & Co. Common Stock for 0 Days on average.

KOOGN
Market Cap
$387.70B$3.62B
Volume
15,313,7832,892,999
Sector
Consumer StaplesHealth
52-Week High
$91.99$13.81
52-Week Low
$67.08$5.70
Typical Hold Time
154 Days0 Days
Enterprise Value
$414.87B$11.04B
Dividend Yield
2.35%0.58%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

The Coca-Cola Co K

Coca-Cola (KO) trades at $91.78, up 2.22% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $95.75. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.97 exceeding expectations, and maintains robust profitability with a 28.56% net income margin. Recent news highlights institutional buying and stable demand trends, though RSI levels indicate potential near-term overbought conditions.

The stock offers a solid dividend profile with 64 consecutive years of increases, but faces risks from regional demand divergence and high valuation multiples. Upside is supported by earnings momentum and institutional accumulation, while macroeconomic pressures and elevated P/E of 27.06 pose caution. The balance between growth execution and market sentiment will drive near-term performance.

Organon & Co. Common Stock

Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.

OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

KO
14% Buy86% Sell
Avg holding period · 154 Days
OGN
100% Buy0% Sell
Avg holding period · 0 Days

Top news

Latest headlines on both assets

About The Coca-Cola Co K

The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.

Read more on KO →

About Organon & Co. Common Stock

Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.

Read more on OGN →